These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30291148)

  • 61. Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation.
    Gkonos PJ; Guo F; Burnstein KL
    Prostate; 2000 Feb; 42(2):137-44. PubMed ID: 10617871
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Cancer stem cells in prostate cancer].
    Nishida S; Masumori N
    Nihon Rinsho; 2014 Dec; 72(12):2229-33. PubMed ID: 25518363
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Stem cells in prostate cancer.
    Mateo F; Fernandez PL; Thomson TM
    Arch Esp Urol; 2013 Jun; 66(5):475-86. PubMed ID: 23793765
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Early human prostate adenocarcinomas harbor androgen-independent cancer cells.
    Fiñones RR; Yeargin J; Lee M; Kaur AP; Cheng C; Sun P; Wu C; Nguyen C; Wang-Rodriguez J; Meyer AN; Baird SM; Donoghue DJ; Haas M
    PLoS One; 2013; 8(9):e74438. PubMed ID: 24086346
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intermediate basal cells of the prostate: in vitro and in vivo characterization.
    Garraway LA; Lin D; Signoretti S; Waltregny D; Dilks J; Bhattacharya N; Loda M
    Prostate; 2003 May; 55(3):206-18. PubMed ID: 12692787
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells.
    He Y; Hooker E; Yu EJ; Cunha GR; Liao L; Xu J; Earl A; Wu H; Gonzalgo ML; Sun Z
    Oncogene; 2019 Mar; 38(13):2337-2350. PubMed ID: 30510232
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The molecular and cellular origin of human prostate cancer.
    Packer JR; Maitland NJ
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1238-60. PubMed ID: 26921821
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
    Sabnis NG; Miller A; Titus MA; Huss WJ
    Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prostate cancer stem cells: do they have a basal or luminal phenotype?
    Maitland NJ; Frame FM; Polson ES; Lewis JL; Collins AT
    Horm Cancer; 2011 Feb; 2(1):47-61. PubMed ID: 21761340
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells.
    Pérez G; López-Moncada F; Indo S; Torres MJ; Castellón EA; Contreras HR
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760173
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization of nonmalignant and malignant prostatic stem/progenitor cells by Hoechst side population method.
    Mimeault M; Batra SK
    Methods Mol Biol; 2009; 568():139-49. PubMed ID: 19582424
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells.
    Russo MA; Ravenna L; Pellegrini L; Petrangeli E; Salvatori L; Magrone T; Fini M; Tafani M
    Endocr Metab Immune Disord Drug Targets; 2016; 16(4):235-248. PubMed ID: 27908264
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A luminal epithelial stem cell that is a cell of origin for prostate cancer.
    Wang X; Kruithof-de Julio M; Economides KD; Walker D; Yu H; Halili MV; Hu YP; Price SM; Abate-Shen C; Shen MM
    Nature; 2009 Sep; 461(7263):495-500. PubMed ID: 19741607
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
    Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.
    Schroeder A; Herrmann A; Cherryholmes G; Kowolik C; Buettner R; Pal S; Yu H; Müller-Newen G; Jove R
    Cancer Res; 2014 Feb; 74(4):1227-37. PubMed ID: 24177177
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Silencing KRAS overexpression in arsenic-transformed prostate epithelial and stem cells partially mitigates malignant phenotype.
    Ngalame NN; Tokar EJ; Person RJ; Waalkes MP
    Toxicol Sci; 2014 Dec; 142(2):489-96. PubMed ID: 25273566
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The path toward identifying prostatic stem cells.
    Taylor RA; Risbridger GP
    Differentiation; 2008 Jul; 76(6):671-81. PubMed ID: 18752495
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.
    Galoczova M; Nenutil R; Pokorna Z; Vojtesek B; Coates PJ
    Virchows Arch; 2021 Apr; 478(4):627-636. PubMed ID: 33037932
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Methodologies in assaying prostate cancer stem cells.
    Li H; Jiang M; Honorio S; Patrawala L; Jeter CR; Calhoun-Davis T; Hayward SW; Tang DG
    Methods Mol Biol; 2009; 568():85-138. PubMed ID: 19582423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.